Last reviewed · How we verify
NCT05192850
Endometrial Cancer Recurrence in Patients Taking Metformin
trial testing Metformin use in Recurrent Endometrial Carcinoma. Withdrawn.
27 February 2023
Quick facts
| Lead sponsor | WellSpan Health |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 27 December 2021 |
| Primary completion | 27 February 2023 |
| Estimated completion | 27 February 2023 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Metformin use — full drug profile →
Conditions studied
- Recurrent Endometrial Carcinoma — all drugs for Recurrent Endometrial Carcinoma →
Sponsor
WellSpan Health — full company profile →
Who can join
Adults 18 to 99, female only, with Recurrent Endometrial Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Given the early literature available and its biological plausibility as an inhibitor of the mammalian target of rapamycin (mTOR) protein, it is hypothesized that women with endometrial cancer who take metformin for non-cancer related reasons have a lower cancer recurrence rate compared to women not taking metformin. The primary goal of this study is to determine whether metformin use is associated with a decrease in the rate of endometrial cancer recurrence. Secondary objectives are to assess whether women with endometrial cancer taking metformin have longer progression free survival and overall survival than those that do not take metformin.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy.
Weth FR, Hoggarth GB, Weth AF, Paterson E, et al · · 2024 · cited 112× · PMID 38012383 · DOI 10.1038/s41416-023-02502-9 -
Metformin: A Dual-Role Player in Cancer Treatment and Prevention.
Galal MA, Al-Rimawi M, Hajeer A, Dahman H, et al · · 2024 · cited 44× · PMID 38612893 · DOI 10.3390/ijms25074083
Verify or expand the search:
- PubMed search for NCT05192850
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Endometrial Carcinoma
Currently open trials in the same condition.
- NCT07198074 — Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With · Phase 3 · recruiting
- NCT06518564 — Avelumab and M1774 in ARID1A-mutated Endometrial Cancer · Phase 2 · recruiting
- NCT05950464 — Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endo · Phase 1 · recruiting
- NCT05691504 — Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers · Phase 1 · active not recruiting
- NCT05554328 — Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway M · Phase 2 · recruiting
Other WellSpan Health trials
Trials by the same sponsor.
- NCT06507670 — Point of Care Ultrasound for the Detection of Esophageal Food Bolus · recruiting
- NCT06779526 — Effect of Four-Week Wellness Program on Work Engagement Burnout and Sleep in a Healthcare Organization (WEBS) · NA · completed
- NCT05748366 — Ultrasound Guided Serratus Anterior Plane Block for Rib Fractures · NA · recruiting
- NCT05538273 — Optimal Management of Urinary Catheter in Gyn Onc · withdrawn
- NCT05082246 — Impact of Complimentary and Alternative Practices on Patient Wellbeing During Rehabilitation · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05192850 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by WellSpan Health
- Last refreshed: 28 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05192850.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing